Home/Pipeline/ENTR-701

ENTR-701

Myotonic Dystrophy Type 1

Phase 1Active

Key Facts

Indication

Myotonic Dystrophy Type 1

Phase

Phase 1

Status

Active

Company

Entrada Therapeutics

About Entrada Therapeutics

Entrada Therapeutics is a clinical-stage biotechnology company with a mission to overcome the fundamental challenge of intracellular drug delivery. Its core innovation is the Endosomal Escape Vehicle (EEV) platform, a versatile technology enabling the efficient delivery of therapeutic molecules into the cell cytoplasm. The company is advancing a pipeline of oligonucleotide-based candidates for serious genetic neuromuscular disorders, with its lead program, ENTR-601-44 for DMD exon 44 skipping, in Phase 1/2b trials. Entrada's strategy leverages its platform to target high-unmet-need diseases with validated biology but historically inaccessible targets.

View full company profile

Therapeutic Areas

Neuromuscular Metabolic Retinal

Other Myotonic Dystrophy Type 1 Drugs

Drug	Company	Phase	Status
JUV-161	Juvena Therapeutics	Phase 1	Active
DM1 Therapy	Kinea Bio	Research	Active
PPR Editor for DM1	EditForce	Preclinical	Active